查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
特應性皮炎治療藥物全球市場規模,份額和行業趨勢分析報告：按給藥途徑,類別（生物製劑,神經鈣蛋白抑製劑,皮質類固醇,PDE4抑製劑）區域展望和預測2022-2028
市場調查報告書
商品編碼
1173206

特應性皮炎治療藥物全球市場規模,份額和行業趨勢分析報告：按給藥途徑,類別（生物製劑,神經鈣蛋白抑製劑,皮質類固醇,PDE4抑製劑）區域展望和預測2022-2028

Global Atopic Dermatitis Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration, By Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors), By Regional Outlook and Forecast, 2022 - 2028
出版日期: | 出版商: KBV Research | 英文 175 Pages | 訂單完成後即時交付

價格

到 2028 年，特應性皮炎療法的全球市場規模預計將達到 220 億美元，預測期內復合年增長率為 9.2%。

特應性皮炎可在任何年齡發病，但通常首先出現在兒童時期，其嚴重程度隨時間而變化。 在 1 歲以下的兒童中，身體的許多部位都會受到影響。 隨著孩子年齡的增長，內側膝蓋和肘部是最常受影響的區域。 在成年人中，它最常見於手腳。

抓撓患處會加重病情，抓撓者更容易發生皮膚感染。 特應性皮炎通常會導致哮喘和花粉熱。 治療包括避免加重疾病的事物、定期洗澡和使用保濕霜、出現症狀時使用類固醇霜以及減少瘙癢的藥物。

羊毛衣物、肥皂、香水、灰塵、氯氣和香煙煙霧是經常加重症狀的一些因素。 光療可能對某些人有幫助。 當其他治療無效時，可使用類固醇藥片和基於鈣調神經磷酸□抑製劑的洗劑。 如果有細菌感染，應給予抗生素（口服或外用）。 只有在檢測到食物過敏時才需要飲食治療。

COVID-19 影響分析

冠狀病毒正在全球範圍內給人們的生活帶來問題，擾亂從社交互動到醫療保健再到我們看待外部世界的方式等方方面面。 由於大流行，所有行業的利潤和產量都在下降。 然而，由於患者就診不規律，特應性皮炎治療市場預計將受到嚴重影響。 即使在這種情況下，遠程皮膚病學仍在繼續發展，因為絕大多數患者無需看醫生就能接受常規和後續護理。

市場增長因素

對生物製劑的需求不斷增長

皮膚病的治療，尤其是特應性皮炎，已經通過在皮膚病學中使用生物製劑而發生了轉變。 生物製劑能夠很好地應對特應性皮炎並改善整體生活質量。 因此，現在對特應性皮炎的生物治療的需求不斷增長。 這種模式可能會在未來幾年繼續下去。 目前只有一種生物製劑被批准用於治療特應性皮炎。 許多產品目前正在進行二期臨床試驗，並可能在不久的將來獲得批准。

特應性皮炎患病率上升

預計推動特應性皮炎藥物市場的主要因素是全球特應性皮炎患者數量的增加。 許多人患有特應性皮炎，預計未來幾年這一數字還會增加。 地理條件、氣候條件、社會經濟地位、生活方式、年齡、性別、遺傳和個人行為都會影響世界範圍內特應性皮炎的患病率。 特應性皮炎必須與日常過敏有關。

市場製約因素

外用類固醇的副作用

少於 4 週的局部類固醇治療通常沒有風險或問題。 長期使用局部類固醇和頻繁短劑量使用高刺激性類固醇會引起問題。 一個主要問題是長期使用強效類固醇。 溫和的局部類固醇幾乎沒有副作用。 外用類固醇具有局部和全身副作用。 系統性是影響整個個體的問題，局部性是影響皮膚特定區域的問題。

班級展望

根據類別，特應性皮炎治療市場分為皮質類固醇、神經鈣蛋白抑製劑、PDE4 抑製劑、生物製劑等。 到 2021 年，皮質類固醇部分在特應性皮炎治療市場中佔有重要的收入份額。 可的松、氫化可的松和潑尼松等皮質類固醇藥物可以成功治療炎症性腸病、皮疹和哮喘等許多病症。

管理路線展望

根據給藥途徑，特應性皮炎藥物市場分為外用劑、注射劑和口服劑。 注射劑將在 2021 年的特應性皮炎藥物市場中佔據最大的收入份額。 這是由於像 dupilumab 這樣的注射劑越來越受歡迎。 Tofacitinib 和 ruxolitinib 是其他正在臨床試驗中研究的可注射生物製劑。 在不久的將來，生物製劑有望改變 AD 治療格局。

區域展望

按地區分析了北美、歐洲、亞太地區和 LAMEA 的特應性皮炎治療市場。 2021 年，北美地區將以最高的收入份額引領特應性皮炎治療市場。 成熟的研發基礎設施和友好的報銷規則是該地區持續佔據主導地位的兩個關鍵因素。 此外，隨著該領域研究的快速發展，監管和報銷環境也在不斷變化。

收購是市場進入者採取的主要策略。 根據 Cardinal Matrix 中的分析，Pfizer和Novartis AG在特應性皮炎藥物市場處於領先地位。 AbbVie, Inc.、Sanofi SA 和 Regeneron Pharmaceuticals Inc. 等公司是特應性皮炎治療市場的一些領先創新者。

內容

第一章市場範圍與研究方法

  • 市場定義
  • 目的
  • 市場規模
  • 細分
    • 按給藥途徑劃分的特應性皮炎藥物全球市場
    • 全球特應性皮炎藥物市場：按類別分類
    • 按地區分列的特應性皮炎藥物全球市場
  • 調查方法

第 2 章市場概述

  • 簡介
    • 概覽
      • 市場構成和情景
  • 影響市場的主要因素
    • 市場驅動因素
    • 市場製約因素

第 3 章競爭分析 - 世界

  • KBV 基數矩陣
  • 近期的全行業戰略發展
    • 收購與合併
    • 批准和試用
  • 關鍵成功策略
    • 關鍵關鍵策略：百分比分佈（2018-2022 年）
    • 主要戰略變動：（收購和合併：2018 年 9 月至 2022 年 10 月）主要參與者

第 4 章特應性皮炎藥物的全球市場：按給藥途徑分類

  • 全球注射劑市場，按地區劃分
  • 全球口服藥市場：按地區
  • 全球外用市場：按地區

第 5 章特應性皮炎藥物的全球市場：按類別分類

  • 全球生物製品市場：按地區
  • 鈣調神經磷酸□抑製劑的全球市場，按區域劃分
  • 皮質類固醇全球市場：按地區
  • 按地區劃分的 PDE4 抑製劑全球市場
  • 世界其他地區的世界市場

第 6 章全球特應性皮炎藥物市場區域

  • 北美
    • 按國家/地區劃分的北美特應性皮炎藥物市場
      • 美國
      • 加拿大
      • 墨西哥
      • 其他北美地區
  • 歐洲
    • 按國家/地區劃分的歐洲特應性皮炎藥物市場
      • 德國
      • 英國
      • 法國
      • 俄羅斯
      • 西班牙
      • 意大利
      • 其他歐洲
  • 亞太地區
    • 亞太地區特應性皮炎藥物市場：按國家/地區分類
      • 中國
      • 日本
      • 印度
      • 韓國
      • 新加坡
      • 馬來西亞
      • 其他亞太地區
  • 拉美
    • LAMEA 特應性皮炎藥物市場：按國家/地區分類
      • 巴西
      • 阿根廷
      • 阿聯酋
      • 沙特阿拉伯
      • 南非
      • 尼日利亞
      • 其他拉美地區

第七章公司簡介

  • Pfizer, Inc.
  • Novartis AG
  • Sanofi S.A
  • LEO Pharma A/S
  • Incyte Corporation
  • AbbVie, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Eli Lilly And Company
  • Otsuka Pharmaceutical Co., Ltd.
  • Galderma S.A

The Global Atopic Dermatitis Drugs Market size is expected to reach $22 billion by 2028, rising at a market growth of 9.2% CAGR during the forecast period.

Eczema, commonly referred to as atopic dermatitis, is a skin ailment that affects the skin and results in itching, dryness, and inflammation. The illness has a potential for chronicity and occasionally flares up and spreads. Drugs for atopic dermatitis, such as atopic eczema steroids, are utilized to treat eczema, lessen itching, and treat other atopic dermatitis-related disorders.

Atopic dermatitis patients run the risk of acquiring asthma, hay fever, and food allergies. Regular moisturizing and other skin care practices help reduce itching and stop future outbreaks. Medicated lotions or ointments may also be used during treatment. It causes skin that is scratchy, red, swollen, and cracked. The damaged sites may leak a clear fluid that thickens over time.

Although the disorder can strike at any age, it usually first manifests in childhood and varies in severity throughout time. Much of the body may be impacted in youngsters under the age of one year. The areas on the inside of the knees and elbows are most frequently affected as kids age. Adults are more frequently afflicted in the hands and feet.

Scratching the affected regions makes the symptoms worse, and individuals who are scratching have a higher chance of developing skin infections. Atopic dermatitis frequently leads to the development of asthma or hay fever. Avoiding things that aggravate the illness, regular bathing followed by the use of moisturizing cream, using steroid creams when flare-ups happen, and drugs to relieve itching are all part of the treatment.

Wool garments, soaps, fragrances, dust, chlorine, and cigarette smoke are a few things that frequently aggravate it. Some people may benefit from phototherapy. If other treatments are ineffective, steroid tablets or lotions based on calcineurin inhibitors may occasionally be employed. If a bacterial infection manifests, antibiotics (by mouth or topically) could be required. Only if food allergies are detected are dietary modifications required.

COVID-19 Impact Analysis

The coronavirus is still creating trouble in people's lives on a worldwide scale, disrupting everything from social interactions to how they seek medical care and see the outside world. Every industry has experienced a profit or output decrease as a result of the pandemic epidemic. However, the market for treating atopic dermatitis has anticipated a substantial impact because of the irregularity of hospital visits by patients. Teledermatology has grown during the crisis when the majority of patients continue to receive generalized care and/or additional consultative therapies without seeing a doctor in person.

Market Growth Factors

Growing Demand For Biologics

The treatment of dermatological disorders, particularly atopic dermatitis, has changed as a result of the use of biologic drugs in dermatology. Biologics have demonstrated a good response to atopic dermatitis, improving the overall quality of life. As a result, there is now a greater demand for biologic treatments for atopic dermatitis. In the upcoming several years, this pattern is probably going to continue. For the time being, only one biologic product has been authorized for the treatment of atopic dermatitis. Many more are currently through phase II clinical studies and will probably be approved soon.

Rising Prevalence Of Atopic Dermatitis

The increasing prevalence of atopic dermatitis medications around the world is anticipated to be the main factor driving the market for atopic dermatitis medications. A large number of people suffer with atopic dermatitis which is expected to rise even more in upcoming years. Geographical location, climatic circumstances, socioeconomic level, lifestyle, age, gender, inheritance, and individual behaviors all have an impact on the prevalence of dermatological problems around the world. An individual with atopic dermatitis must deal with allergies on a daily basis.

Market Restraining Factors

Side Effects Of Topical Steroids

Topical steroid treatments lasting fewer than four weeks are often risk-free and trouble-free. Long-term topical steroid use or frequent repetition of short doses of harsher steroids may cause issues. The primary issue is the prolonged usage of potent steroids. Mild topical steroids rarely have side effects. Topical steroids may have local or systemic side effects. Systemic refers to an issue that affects the entire individual, whereas local refers to that particular area of skin.

Class Outlook

Based on class, the atopic dermatitis drugs market is segmented into corticosteroids, calcineurin inhibitors, PDE4 inhibitors, biologics and others. In 2021, the corticosteroids segment acquired a substantial revenue share in the atopic dermatitis drugs market. Many conditions, such as inflammatory bowel disease, rashes, and asthma, can be successfully treated with corticosteroid medications, such as cortisone, hydrocortisone, and prednisone.

Route Of Administration Outlook

On the basis of route of administration, the atopic dermatitis drugs market is fragmented into topical, injectable and oral. In 2021, the injectable segment held the largest revenue share in the atopic dermatitis drugs market. This is due to the rising popularity of injectable drugs like Dupilumab. Tofacitinib and ruxolitinib are other injectable biologics being studied in clinical trials. In the near future, biologics are anticipated to alter the therapy landscape for AD.

Regional Outlook

Region wise, the atopic dermatitis drugs market is analyzed across North America, Europe, Asia Pacific and LAMEA. In 2021, the North America region led the atopic dermatitis drugs market by generating the highest revenue share. The availability of a well-established R&D infrastructure and kind reimbursement rules are two major factors contributing to the region's sustained dominance. Additionally, the regulatory and reimbursement environment is constantly changing to keep up with the rapid advancement of research in this field.

The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc. and Novartis AG are the forerunners in the Atopic Dermatitis Drugs Market. Companies such as AbbVie, Inc., Sanofi SA, Regeneron Pharmaceuticals Inc. are some of the key innovators in Atopic Dermatitis Drugs Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer Inc., Sanofi SA, AbbVie Inc., Galderma S.A., Eli Lilly and Company, Leo Pharma A/S, Regeneron Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and Incyte Corporation.

Recent Strategies Deployed in Atopic Dermatitis Drugs Market

Mergers and Acquisitions:

Oct-2022: Incyte completed the acquisition of Villaris Therapeutics, an asset-centric biopharmaceutical company. This acquisition would complement Incyte's current portfolio, providing Incyte the opportunity to improve treatment options for people with vitiligo, that leverage the expertise established in the dermatology space.

Jun-2022: Pfizer took over ReViral, a privately held, clinical-stage Biopharmaceutical Company. This acquisition further demonstrates Pfizer's commitment to advancing pioneering science both through its in-house expertise and work with leading, innovative companies - with the aim to deliver breakthroughs to patients suffering from severe infectious diseases.

Mar-2022: Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, Pfizer would add the impressive experience and pipeline of Arena Pharmaceuticals to Pfizer's Inflammation & Immunology therapeutic area, helping the company further its purpose of developing breakthroughs to change the lives of those with immuno-inflammatory diseases.

Jan-2022: Galderma took over ALASTIN Skincare, a specialty aesthetics company. This acquisition aimed at enhancing Galderma's integrated dermatology platform with a comprehensive collection of scientifically-approved products for daily skincare regimens and peri-procedural use. Also, the acquisition would underscore Galderma's commitment to being the partner of choice for aesthetic professionals.

Dec-2021: AbbVie took over Soliton, a medical device company. The acquisition would complement Allergan Aesthetics' portfolio of non-invasive body contouring treatments to include a proven treatment for the appearance of cellulite.

Nov-2021: Sanofi completed the acquisition of Translate Bio, a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases. The acquisition support Sanofi's mRNA Center of Excellence, which plans to explore the potential of enhanced mRNA vaccines & other key areas that includes immunology, oncology, and rare diseases.

Nov-2021: Sanofi took over Kadmon Holdings, which operates as a biopharmaceutical company. This acquisition would strengthen the expansion & growth of the general medicines portfolio.

Jul-2019: LEO Pharma completed the acquisition of Bayer. LEO Pharma advances significantly towards its goal of helping 125 million patients by 2025. With this acquisition, the LEO considerably improve its size in key markets like Austria, Brazil, and South Africa - underlining its ambition to become a global leader in medical dermatology.

Approvals and Trials:

Oct-2022: LEO Pharma got European approval for Adtralza, a drug to treat moderate-to-severe AD in adolescents. The approval would address LEO's relentless commitment to bringing the latest treatment options for those living with atopic dermatitis. This approval enables LEO to address the unmet needs of a broader patient population as it looks forwards to work with key stakeholders across the Europe region.

Jun-2022: Sanofi got FDA approval for Dupixent, a biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood. The approval would enable the availability of Dupixent for young people with the disease.

Jan-2022: Pfizer got FDA approval for CIBINQO, an oral, once-daily, Janus kinase 1 (JAK1) inhibitor. CIBINQO would offer the treatment of adults living with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products. CIBINQO would provide an important latest oral option that would help those who have yet to find relief.

Jan-2022: AbbVie got FDA approval for RINVOQ, a once-daily oral option that can significantly enhance the debilitating itch & skin symptoms of atopic dermatitis. Through this acquisition, AbbVie would continue its efforts to enhance care in this disease state & other chronic, immune-mediated conditions.

Dec-2021: Leo Pharma got FDA approval for Adbry, an eczema drug. The injected antibody drug would address adults and older who don't get proper relief from topical prescription therapies. Adbry would signify important progress in LEO's aim of enhancing the standard of care in medical dermatology.

Sep-2021: Otsuka got FDA approval for Moizerto Ointment, a treatment for atopic dermatitis. Otsuka expects that Moizerto Ointment would serve as the latest treatment option for people having atopic dermatitis in Japan.

Sep-2021: Incyte got FDA approval for Opzelura, a topical JAK inhibitor to treat AD. With this approval, the company looks forward to bringing Opzelura to the patient community and also continuing to explore its potential in other skin diseases.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration

  • Injectable
  • Oral
  • Topical

By Class

  • Biologics
  • Calcineurin Inhibitors
  • Corticosteroids
  • PDE4 Inhibitors
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Pfizer Inc.
  • Sanofi SA
  • AbbVie Inc.
  • Galderma S.A.
  • Eli Lilly and Company
  • Leo Pharma A/S
  • Regeneron Pharmaceuticals Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Novartis AG
  • Incyte Corporation

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Atopic Dermatitis Drugs Market, by Route of Administration
    • 1.4.2 Global Atopic Dermatitis Drugs Market, by Class
    • 1.4.3 Global Atopic Dermatitis Drugs Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition & Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Acquisition and Mergers
    • 3.2.2 Approvals and Trials
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
    • 3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2018, Sep - 2022, Oct) Leading Players

Chapter 4. Global Atopic Dermatitis Drugs Market by Route of Administration

  • 4.1 Global Injectable Market by Region
  • 4.2 Global Oral Market by Region
  • 4.3 Global Topical Market by Region

Chapter 5. Global Atopic Dermatitis Drugs Market by Class

  • 5.1 Global Biologics Market by Region
  • 5.2 Global Calcineurin Inhibitors Market by Region
  • 5.3 Global Corticosteroids Market by Region
  • 5.4 Global PDE4 Inhibitors Market by Region
  • 5.5 Global Others Market by Region

Chapter 6. Global Atopic Dermatitis Drugs Market by Region

  • 6.1 North America Atopic Dermatitis Drugs Market
    • 6.1.1 North America Atopic Dermatitis Drugs Market by Route of Administration
      • 6.1.1.1 North America Injectable Market by Country
      • 6.1.1.2 North America Oral Market by Country
      • 6.1.1.3 North America Topical Market by Country
    • 6.1.2 North America Atopic Dermatitis Drugs Market by Class
      • 6.1.2.1 North America Biologics Market by Country
      • 6.1.2.2 North America Calcineurin Inhibitors Market by Country
      • 6.1.2.3 North America Corticosteroids Market by Country
      • 6.1.2.4 North America PDE4 Inhibitors Market by Country
      • 6.1.2.5 North America Others Market by Country
    • 6.1.3 North America Atopic Dermatitis Drugs Market by Country
      • 6.1.3.1 US Atopic Dermatitis Drugs Market
        • 6.1.3.1.1 US Atopic Dermatitis Drugs Market by Route of Administration
        • 6.1.3.1.2 US Atopic Dermatitis Drugs Market by Class
      • 6.1.3.2 Canada Atopic Dermatitis Drugs Market
        • 6.1.3.2.1 Canada Atopic Dermatitis Drugs Market by Route of Administration
        • 6.1.3.2.2 Canada Atopic Dermatitis Drugs Market by Class
      • 6.1.3.3 Mexico Atopic Dermatitis Drugs Market
        • 6.1.3.3.1 Mexico Atopic Dermatitis Drugs Market by Route of Administration
        • 6.1.3.3.2 Mexico Atopic Dermatitis Drugs Market by Class
      • 6.1.3.4 Rest of North America Atopic Dermatitis Drugs Market
        • 6.1.3.4.1 Rest of North America Atopic Dermatitis Drugs Market by Route of Administration
        • 6.1.3.4.2 Rest of North America Atopic Dermatitis Drugs Market by Class
  • 6.2 Europe Atopic Dermatitis Drugs Market
    • 6.2.1 Europe Atopic Dermatitis Drugs Market by Route of Administration
      • 6.2.1.1 Europe Injectable Market by Country
      • 6.2.1.2 Europe Oral Market by Country
      • 6.2.1.3 Europe Topical Market by Country
    • 6.2.2 Europe Atopic Dermatitis Drugs Market by Class
      • 6.2.2.1 Europe Biologics Market by Country
      • 6.2.2.2 Europe Calcineurin Inhibitors Market by Country
      • 6.2.2.3 Europe Corticosteroids Market by Country
      • 6.2.2.4 Europe PDE4 Inhibitors Market by Country
      • 6.2.2.5 Europe Others Market by Country
    • 6.2.3 Europe Atopic Dermatitis Drugs Market by Country
      • 6.2.3.1 Germany Atopic Dermatitis Drugs Market
        • 6.2.3.1.1 Germany Atopic Dermatitis Drugs Market by Route of Administration
        • 6.2.3.1.2 Germany Atopic Dermatitis Drugs Market by Class
      • 6.2.3.2 UK Atopic Dermatitis Drugs Market
        • 6.2.3.2.1 UK Atopic Dermatitis Drugs Market by Route of Administration
        • 6.2.3.2.2 UK Atopic Dermatitis Drugs Market by Class
      • 6.2.3.3 France Atopic Dermatitis Drugs Market
        • 6.2.3.3.1 France Atopic Dermatitis Drugs Market by Route of Administration
        • 6.2.3.3.2 France Atopic Dermatitis Drugs Market by Class
      • 6.2.3.4 Russia Atopic Dermatitis Drugs Market
        • 6.2.3.4.1 Russia Atopic Dermatitis Drugs Market by Route of Administration
        • 6.2.3.4.2 Russia Atopic Dermatitis Drugs Market by Class
      • 6.2.3.5 Spain Atopic Dermatitis Drugs Market
        • 6.2.3.5.1 Spain Atopic Dermatitis Drugs Market by Route of Administration
        • 6.2.3.5.2 Spain Atopic Dermatitis Drugs Market by Class
      • 6.2.3.6 Italy Atopic Dermatitis Drugs Market
        • 6.2.3.6.1 Italy Atopic Dermatitis Drugs Market by Route of Administration
        • 6.2.3.6.2 Italy Atopic Dermatitis Drugs Market by Class
      • 6.2.3.7 Rest of Europe Atopic Dermatitis Drugs Market
        • 6.2.3.7.1 Rest of Europe Atopic Dermatitis Drugs Market by Route of Administration
        • 6.2.3.7.2 Rest of Europe Atopic Dermatitis Drugs Market by Class
  • 6.3 Asia Pacific Atopic Dermatitis Drugs Market
    • 6.3.1 Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration
      • 6.3.1.1 Asia Pacific Injectable Market by Country
      • 6.3.1.2 Asia Pacific Oral Market by Country
      • 6.3.1.3 Asia Pacific Topical Market by Country
    • 6.3.2 Asia Pacific Atopic Dermatitis Drugs Market by Class
      • 6.3.2.1 Asia Pacific Biologics Market by Country
      • 6.3.2.2 Asia Pacific Calcineurin Inhibitors Market by Country
      • 6.3.2.3 Asia Pacific Corticosteroids Market by Country
      • 6.3.2.4 Asia Pacific PDE4 Inhibitors Market by Country
      • 6.3.2.5 Asia Pacific Others Market by Country
    • 6.3.3 Asia Pacific Atopic Dermatitis Drugs Market by Country
      • 6.3.3.1 China Atopic Dermatitis Drugs Market
        • 6.3.3.1.1 China Atopic Dermatitis Drugs Market by Route of Administration
        • 6.3.3.1.2 China Atopic Dermatitis Drugs Market by Class
      • 6.3.3.2 Japan Atopic Dermatitis Drugs Market
        • 6.3.3.2.1 Japan Atopic Dermatitis Drugs Market by Route of Administration
        • 6.3.3.2.2 Japan Atopic Dermatitis Drugs Market by Class
      • 6.3.3.3 India Atopic Dermatitis Drugs Market
        • 6.3.3.3.1 India Atopic Dermatitis Drugs Market by Route of Administration
        • 6.3.3.3.2 India Atopic Dermatitis Drugs Market by Class
      • 6.3.3.4 South Korea Atopic Dermatitis Drugs Market
        • 6.3.3.4.1 South Korea Atopic Dermatitis Drugs Market by Route of Administration
        • 6.3.3.4.2 South Korea Atopic Dermatitis Drugs Market by Class
      • 6.3.3.5 Singapore Atopic Dermatitis Drugs Market
        • 6.3.3.5.1 Singapore Atopic Dermatitis Drugs Market by Route of Administration
        • 6.3.3.5.2 Singapore Atopic Dermatitis Drugs Market by Class
      • 6.3.3.6 Malaysia Atopic Dermatitis Drugs Market
        • 6.3.3.6.1 Malaysia Atopic Dermatitis Drugs Market by Route of Administration
        • 6.3.3.6.2 Malaysia Atopic Dermatitis Drugs Market by Class
      • 6.3.3.7 Rest of Asia Pacific Atopic Dermatitis Drugs Market
        • 6.3.3.7.1 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration
        • 6.3.3.7.2 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Class
  • 6.4 LAMEA Atopic Dermatitis Drugs Market
    • 6.4.1 LAMEA Atopic Dermatitis Drugs Market by Route of Administration
      • 6.4.1.1 LAMEA Injectable Market by Country
      • 6.4.1.2 LAMEA Oral Market by Country
      • 6.4.1.3 LAMEA Topical Market by Country
    • 6.4.2 LAMEA Atopic Dermatitis Drugs Market by Class
      • 6.4.2.1 LAMEA Biologics Market by Country
      • 6.4.2.2 LAMEA Calcineurin Inhibitors Market by Country
      • 6.4.2.3 LAMEA Corticosteroids Market by Country
      • 6.4.2.4 LAMEA PDE4 Inhibitors Market by Country
      • 6.4.2.5 LAMEA Others Market by Country
    • 6.4.3 LAMEA Atopic Dermatitis Drugs Market by Country
      • 6.4.3.1 Brazil Atopic Dermatitis Drugs Market
        • 6.4.3.1.1 Brazil Atopic Dermatitis Drugs Market by Route of Administration
        • 6.4.3.1.2 Brazil Atopic Dermatitis Drugs Market by Class
      • 6.4.3.2 Argentina Atopic Dermatitis Drugs Market
        • 6.4.3.2.1 Argentina Atopic Dermatitis Drugs Market by Route of Administration
        • 6.4.3.2.2 Argentina Atopic Dermatitis Drugs Market by Class
      • 6.4.3.3 UAE Atopic Dermatitis Drugs Market
        • 6.4.3.3.1 UAE Atopic Dermatitis Drugs Market by Route of Administration
        • 6.4.3.3.2 UAE Atopic Dermatitis Drugs Market by Class
      • 6.4.3.4 Saudi Arabia Atopic Dermatitis Drugs Market
        • 6.4.3.4.1 Saudi Arabia Atopic Dermatitis Drugs Market by Route of Administration
        • 6.4.3.4.2 Saudi Arabia Atopic Dermatitis Drugs Market by Class
      • 6.4.3.5 South Africa Atopic Dermatitis Drugs Market
        • 6.4.3.5.1 South Africa Atopic Dermatitis Drugs Market by Route of Administration
        • 6.4.3.5.2 South Africa Atopic Dermatitis Drugs Market by Class
      • 6.4.3.6 Nigeria Atopic Dermatitis Drugs Market
        • 6.4.3.6.1 Nigeria Atopic Dermatitis Drugs Market by Route of Administration
        • 6.4.3.6.2 Nigeria Atopic Dermatitis Drugs Market by Class
      • 6.4.3.7 Rest of LAMEA Atopic Dermatitis Drugs Market
        • 6.4.3.7.1 Rest of LAMEA Atopic Dermatitis Drugs Market by Route of Administration
        • 6.4.3.7.2 Rest of LAMEA Atopic Dermatitis Drugs Market by Class

Chapter 7. Company Profiles

  • 7.1 Pfizer, Inc.
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Regional & Segmental Analysis
    • 7.1.4 Research & Development Expense
    • 7.1.5 Recent strategies and developments:
      • 7.1.5.1 Approvals and Trials:
      • 7.1.5.2 Acquisition and Mergers:
  • 7.2 Novartis AG
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Segmental and Regional Analysis
    • 7.2.4 Research & Development Expense
  • 7.3 Sanofi S.A.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expense
    • 7.3.5 Recent strategies and developments:
      • 7.3.5.1 Approvals and Trials:
      • 7.3.5.2 Acquisition and Mergers:
  • 7.4 LEO Pharma A/S
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Regional Analysis
    • 7.4.4 Research & Development Expense
    • 7.4.5 Recent strategies and developments:
      • 7.4.5.1 Approvals and Trials:
      • 7.4.5.2 Acquisition and Mergers:
  • 7.5 Incyte Corporation
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Research & Development Expenses
    • 7.5.4 Recent strategies and developments:
      • 7.5.4.1 Approvals and Trials:
      • 7.5.4.2 Acquisition and Mergers:
  • 7.6 AbbVie, Inc.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Regional Analysis
    • 7.6.4 Research & Development Expense
    • 7.6.5 Recent strategies and developments:
      • 7.6.5.1 Approvals and Trials:
      • 7.6.5.2 Acquisition and Mergers:
  • 7.7 Regeneron Pharmaceuticals, Inc.
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Research & Development Expense
  • 7.8 Eli Lilly And Company
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Regional Analysis
    • 7.8.4 Research & Development Expenses
  • 7.9 Otsuka Pharmaceutical Co., Ltd.
    • 7.9.1 Company Overview
    • 7.9.2 Recent strategies and developments:
      • 7.9.2.1 Approvals and Trials:
      • 7.9.2.2 Acquisition and Mergers:
  • 7.10. Galderma S.A.
    • 7.10.1 Company Overview
    • 7.10.2 Recent strategies and developments:
      • 7.10.2.1 Acquisition and Mergers:

LIST OF TABLES

  • TABLE 1 Global Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 2 Global Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 3 Acquisition and Mergers- Atopic Dermatitis Drugs Market
  • TABLE 4 Approvals and trials - Atopic Dermatitis Drugs Market
  • TABLE 5 Global Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 6 Global Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 7 Global Injectable Market by Region, 2018 - 2021, USD Million
  • TABLE 8 Global Injectable Market by Region, 2022 - 2028, USD Million
  • TABLE 9 Global Oral Market by Region, 2018 - 2021, USD Million
  • TABLE 10 Global Oral Market by Region, 2022 - 2028, USD Million
  • TABLE 11 Global Topical Market by Region, 2018 - 2021, USD Million
  • TABLE 12 Global Topical Market by Region, 2022 - 2028, USD Million
  • TABLE 13 Global Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 14 Global Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 15 Global Biologics Market by Region, 2018 - 2021, USD Million
  • TABLE 16 Global Biologics Market by Region, 2022 - 2028, USD Million
  • TABLE 17 Global Calcineurin Inhibitors Market by Region, 2018 - 2021, USD Million
  • TABLE 18 Global Calcineurin Inhibitors Market by Region, 2022 - 2028, USD Million
  • TABLE 19 Global Corticosteroids Market by Region, 2018 - 2021, USD Million
  • TABLE 20 Global Corticosteroids Market by Region, 2022 - 2028, USD Million
  • TABLE 21 Global PDE4 Inhibitors Market by Region, 2018 - 2021, USD Million
  • TABLE 22 Global PDE4 Inhibitors Market by Region, 2022 - 2028, USD Million
  • TABLE 23 Global Others Market by Region, 2018 - 2021, USD Million
  • TABLE 24 Global Others Market by Region, 2022 - 2028, USD Million
  • TABLE 25 Global Atopic Dermatitis Drugs Market by Region, 2018 - 2021, USD Million
  • TABLE 26 Global Atopic Dermatitis Drugs Market by Region, 2022 - 2028, USD Million
  • TABLE 27 North America Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 28 North America Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 29 North America Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 30 North America Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 31 North America Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 32 North America Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 33 North America Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 34 North America Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 35 North America Topical Market by Country, 2018 - 2021, USD Million
  • TABLE 36 North America Topical Market by Country, 2022 - 2028, USD Million
  • TABLE 37 North America Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 38 North America Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 39 North America Biologics Market by Country, 2018 - 2021, USD Million
  • TABLE 40 North America Biologics Market by Country, 2022 - 2028, USD Million
  • TABLE 41 North America Calcineurin Inhibitors Market by Country, 2018 - 2021, USD Million
  • TABLE 42 North America Calcineurin Inhibitors Market by Country, 2022 - 2028, USD Million
  • TABLE 43 North America Corticosteroids Market by Country, 2018 - 2021, USD Million
  • TABLE 44 North America Corticosteroids Market by Country, 2022 - 2028, USD Million
  • TABLE 45 North America PDE4 Inhibitors Market by Country, 2018 - 2021, USD Million
  • TABLE 46 North America PDE4 Inhibitors Market by Country, 2022 - 2028, USD Million
  • TABLE 47 North America Others Market by Country, 2018 - 2021, USD Million
  • TABLE 48 North America Others Market by Country, 2022 - 2028, USD Million
  • TABLE 49 North America Atopic Dermatitis Drugs Market by Country, 2018 - 2021, USD Million
  • TABLE 50 North America Atopic Dermatitis Drugs Market by Country, 2022 - 2028, USD Million
  • TABLE 51 US Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 52 US Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 53 US Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 54 US Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 55 US Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 56 US Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 57 Canada Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 58 Canada Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 59 Canada Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 60 Canada Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 61 Canada Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 62 Canada Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 63 Mexico Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 64 Mexico Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 65 Mexico Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 66 Mexico Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 67 Mexico Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 68 Mexico Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 69 Rest of North America Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 70 Rest of North America Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 71 Rest of North America Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 72 Rest of North America Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 73 Rest of North America Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 74 Rest of North America Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 75 Europe Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 76 Europe Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 77 Europe Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 78 Europe Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 79 Europe Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 80 Europe Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 81 Europe Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 82 Europe Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 83 Europe Topical Market by Country, 2018 - 2021, USD Million
  • TABLE 84 Europe Topical Market by Country, 2022 - 2028, USD Million
  • TABLE 85 Europe Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 86 Europe Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 87 Europe Biologics Market by Country, 2018 - 2021, USD Million
  • TABLE 88 Europe Biologics Market by Country, 2022 - 2028, USD Million
  • TABLE 89 Europe Calcineurin Inhibitors Market by Country, 2018 - 2021, USD Million
  • TABLE 90 Europe Calcineurin Inhibitors Market by Country, 2022 - 2028, USD Million
  • TABLE 91 Europe Corticosteroids Market by Country, 2018 - 2021, USD Million
  • TABLE 92 Europe Corticosteroids Market by Country, 2022 - 2028, USD Million
  • TABLE 93 Europe PDE4 Inhibitors Market by Country, 2018 - 2021, USD Million
  • TABLE 94 Europe PDE4 Inhibitors Market by Country, 2022 - 2028, USD Million
  • TABLE 95 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 96 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 97 Europe Atopic Dermatitis Drugs Market by Country, 2018 - 2021, USD Million
  • TABLE 98 Europe Atopic Dermatitis Drugs Market by Country, 2022 - 2028, USD Million
  • TABLE 99 Germany Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 100 Germany Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 101 Germany Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 102 Germany Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 103 Germany Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 104 Germany Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 105 UK Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 106 UK Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 107 UK Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 108 UK Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 109 UK Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 110 UK Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 111 France Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 112 France Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 113 France Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 114 France Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 115 France Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 116 France Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 117 Russia Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 118 Russia Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 119 Russia Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 120 Russia Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 121 Russia Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 122 Russia Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 123 Spain Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 124 Spain Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 125 Spain Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 126 Spain Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 127 Spain Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 128 Spain Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 129 Italy Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 130 Italy Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 131 Italy Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 132 Italy Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 133 Italy Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 134 Italy Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 135 Rest of Europe Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 136 Rest of Europe Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 137 Rest of Europe Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 138 Rest of Europe Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 139 Rest of Europe Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 140 Rest of Europe Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 141 Asia Pacific Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 142 Asia Pacific Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 143 Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 144 Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 145 Asia Pacific Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 146 Asia Pacific Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 147 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 148 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 149 Asia Pacific Topical Market by Country, 2018 - 2021, USD Million
  • TABLE 150 Asia Pacific Topical Market by Country, 2022 - 2028, USD Million
  • TABLE 151 Asia Pacific Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 152 Asia Pacific Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 153 Asia Pacific Biologics Market by Country, 2018 - 2021, USD Million
  • TABLE 154 Asia Pacific Biologics Market by Country, 2022 - 2028, USD Million
  • TABLE 155 Asia Pacific Calcineurin Inhibitors Market by Country, 2018 - 2021, USD Million
  • TABLE 156 Asia Pacific Calcineurin Inhibitors Market by Country, 2022 - 2028, USD Million
  • TABLE 157 Asia Pacific Corticosteroids Market by Country, 2018 - 2021, USD Million
  • TABLE 158 Asia Pacific Corticosteroids Market by Country, 2022 - 2028, USD Million
  • TABLE 159 Asia Pacific PDE4 Inhibitors Market by Country, 2018 - 2021, USD Million
  • TABLE 160 Asia Pacific PDE4 Inhibitors Market by Country, 2022 - 2028, USD Million
  • TABLE 161 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 162 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 163 Asia Pacific Atopic Dermatitis Drugs Market by Country, 2018 - 2021, USD Million
  • TABLE 164 Asia Pacific Atopic Dermatitis Drugs Market by Country, 2022 - 2028, USD Million
  • TABLE 165 China Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 166 China Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 167 China Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 168 China Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 169 China Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 170 China Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 171 Japan Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 172 Japan Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 173 Japan Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 174 Japan Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 175 Japan Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 176 Japan Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 177 India Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 178 India Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 179 India Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 180 India Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 181 India Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 182 India Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 183 South Korea Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 184 South Korea Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 185 South Korea Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 186 South Korea Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 187 South Korea Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 188 South Korea Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 189 Singapore Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 190 Singapore Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 191 Singapore Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 192 Singapore Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 193 Singapore Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 194 Singapore Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 195 Malaysia Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 196 Malaysia Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 197 Malaysia Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 198 Malaysia Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 199 Malaysia Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 200 Malaysia Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 201 Rest of Asia Pacific Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 202 Rest of Asia Pacific Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 203 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 204 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 205 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 206 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 207 LAMEA Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 208 LAMEA Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 209 LAMEA Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 210 LAMEA Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 211 LAMEA Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 212 LAMEA Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 213 LAMEA Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 214 LAMEA Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 215 LAMEA Topical Market by Country, 2018 - 2021, USD Million
  • TABLE 216 LAMEA Topical Market by Country, 2022 - 2028, USD Million
  • TABLE 217 LAMEA Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 218 LAMEA Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 219 LAMEA Biologics Market by Country, 2018 - 2021, USD Million
  • TABLE 220 LAMEA Biologics Market by Country, 2022 - 2028, USD Million
  • TABLE 221 LAMEA Calcineurin Inhibitors Market by Country, 2018 - 2021, USD Million
  • TABLE 222 LAMEA Calcineurin Inhibitors Market by Country, 2022 - 2028, USD Million
  • TABLE 223 LAMEA Corticosteroids Market by Country, 2018 - 2021, USD Million
  • TABLE 224 LAMEA Corticosteroids Market by Country, 2022 - 2028, USD Million
  • TABLE 225 LAMEA PDE4 Inhibitors Market by Country, 2018 - 2021, USD Million
  • TABLE 226 LAMEA PDE4 Inhibitors Market by Country, 2022 - 2028, USD Million
  • TABLE 227 LAMEA Others Market by Country, 2018 - 2021, USD Million
  • TABLE 228 LAMEA Others Market by Country, 2022 - 2028, USD Million
  • TABLE 229 LAMEA Atopic Dermatitis Drugs Market by Country, 2018 - 2021, USD Million
  • TABLE 230 LAMEA Atopic Dermatitis Drugs Market by Country, 2022 - 2028, USD Million
  • TABLE 231 Brazil Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 232 Brazil Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 233 Brazil Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 234 Brazil Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 235 Brazil Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 236 Brazil Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 237 Argentina Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 238 Argentina Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 239 Argentina Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 240 Argentina Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 241 Argentina Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 242 Argentina Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 243 UAE Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 244 UAE Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 245 UAE Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 246 UAE Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 247 UAE Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 248 UAE Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 249 Saudi Arabia Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 250 Saudi Arabia Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 251 Saudi Arabia Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 252 Saudi Arabia Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 253 Saudi Arabia Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 254 Saudi Arabia Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 255 South Africa Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 256 South Africa Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 257 South Africa Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 258 South Africa Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 259 South Africa Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 260 South Africa Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 261 Nigeria Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 262 Nigeria Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 263 Nigeria Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 264 Nigeria Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 265 Nigeria Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 266 Nigeria Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 267 Rest of LAMEA Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
  • TABLE 268 Rest of LAMEA Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
  • TABLE 269 Rest of LAMEA Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 270 Rest of LAMEA Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 271 Rest of LAMEA Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
  • TABLE 272 Rest of LAMEA Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
  • TABLE 273 Key Information - Pfizer, Inc.
  • TABLE 274 Key Information - Novartis AG
  • TABLE 275 Key Information - Sanofi S.A.
  • TABLE 276 key information - LEO Pharma A/S
  • TABLE 277 Key Information - INCYTE CORPORATION
  • TABLE 278 Key information - AbbVie, Inc.
  • TABLE 279 Key Information - Regeneron Pharmaceuticals, Inc.
  • TABLE 280 Key Information - Eli Lilly And Company
  • TABLE 281 key information - Otsuka Pharmaceutical Co., Ltd.
  • TABLE 282 Key Information - Galderma S.A.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
  • FIG 4 Key Strategic Move: (Acquisitions and Mergers: 2018, SeP - 2022, Oct) Leading Players
  • FIG 5 Global Atopic Dermatitis Drugs Market Share by Route of Administration, 2021
  • FIG 6 Global Atopic Dermatitis Drugs Market Share by Route of Administration, 2028
  • FIG 7 Global Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2028, USD Million
  • FIG 8 Global Atopic Dermatitis Drugs Market Share by Class, 2021
  • FIG 9 Global Atopic Dermatitis Drugs Market Share by Class, 2028
  • FIG 10 Global Atopic Dermatitis Drugs Market by Class, 2018 - 2028, USD Million
  • FIG 11 Global Atopic Dermatitis Drugs Market Share by Region, 2021
  • FIG 12 Global Atopic Dermatitis Drugs Market Share by Region, 2028
  • FIG 13 Global Atopic Dermatitis Drugs Market by Region, 2018 - 2028, USD Million
  • FIG 14 Recent strategies and developments: Pfizer, Inc.
  • FIG 15 Recent strategies and developments: sanofi s.a.
  • FIG 16 Recent strategies and developments: leo pharma a/s